Pilot Study of twice-weekly therapy for pulmonary tuberculosis in Taiwan

Journal of the Formosan Medical Association

Volumn 110, Issue 7, 2011, Pages 438-445

  Lin, Chih Bin ^a   Tang, Meng ^a   Hsu, Ai Hsi ^a   Miu, Wei Chieh ^b   Lee, Yeong Sheng ^c   Lee, Jen Jyh ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b Mennonite Christian Hospital   (Taiwan)

^c CENTER FOR DISEASE CONTROL   (Taiwan)

Author keywords

Directly observed therapy (DOT); Intermittent therapy; Pulmonary tuberculosis recurrence; Treatment outcome

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ACID FAST BACTERIUM; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; BACTERIUM CULTURE; BLURRED VISION; CLINICAL EVALUATION; DIRECTLY OBSERVED THERAPY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL INTOLERANCE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER DYSFUNCTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PILOT STUDY; PRURITUS; RASH; RECURRENT INFECTION; SPUTUM CULTURE; TAIWAN; THORAX RADIOGRAPHY; TREATMENT DURATION; VOMITING;

EID: 79960766912     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(11)60065-X     Document Type: Article

References (28)

1. Centers for Disease Control, Department of Health, Taiwan. Tuberculosis control report 2009.
2. th edition. Paris: International Union Against Tuberculosis and Lung Disease, 2000.
3. rd edition. Geneva WHO 2003;313:1-108.
4. World Bank. World Development Report 1993: Investing in Health. Oxford: Oxford University Press, 1993.
5. World Health Organization. Forty-fourth world health assembly, resolutions and decisions. Geneva WHO 1991; WHA44/1991/REC/1.
6. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. Geneva WHO 2009;WHO/HTM/TB/2009.411.
7. Lee JJ, Wu RL, Lee YS, et al. Treatment outcome of pulmonary tuberculosis in eastern Taiwan-an experience at a medical center. J Formos Med Assoc 2007;106:25-30.
8. American thoracic society/centers for disease control and prevention/infectious diseases society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-62.
9. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002;360:528-34.
10. Chang KC, Leung CC, Yew WW, et al. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004;170:1124-30.
11. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO Report 2004. Geneva WHO;2004;WHO/HTM/TB/2004.331.
12. Falzon D. Revised international definitions in tuberculosis control: comments from the Aral Sea Area tuberculosis programme. Int J Tuberc Lung Dis 2001;5:1071-2.
13. American Thoracic Society. Guidelines for short-course tuberculosis chemotherapy. Am Rev Respir Dis 1980;121: 611-4.
14. Combs DL, O'Brien RJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990;112:397-406.
15. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the public health tuberculosis guidelines panel. JAMA 1998;279:943-8.
16. Jasmer RM, Seaman CB, Gonzalez LC, et al. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med 2004;170:561-6.
17. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330: 1179-84.
18. WHO report on the tuberculosis epidemic, 1995. Stop TB at the source. Geneva WHO 1995;WHO/TB/95.183.
19. Chiang CY, Centis R, Migliori GB. Drug-resistant tuberculosis: past, present, future. Respirology 2010;15:413-32.
20. Cox HS, Morrow M, Deutschmann PW. Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ 2008;336:484-7.
21. Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996;154:1034-8.
22. Dholakia Y, Danani U, Desai C. Relapse following directly observed therapy short course (DOTS)-a follow up study. Indian J Tuberc 2000;47:233-6.
23. Thomas A, Gopi PG, Santha T, et al. Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. Int J Tuberc Lung Dis 2005;9: 556-61.
24. Malkin JE, Prazuck T, Simonnet F, et al. Tuberculosis and human immunodeficiency virus infection in west Burkina Faso: clinical presentation and clinical evolution. Int J Tuberc Lung Dis 1997;1:68-74.
25. Mohanty KC, Dhamgaye TM. Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. Chest 1993;104:1194-8.
26. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Am Rev Respir Dis 1991;143:700-6.
27. Cohn DL, Catlin BJ, Peterson KL, et al. A 62-dose, 6-motherapy for pulmonary and extrapulmonary tuberculosis. Ann Intern Med 1990;112:407-15.
28. Mitchison DA. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 2005;171:699-706.